Clinical trials: Tacrolimus, completed
Kidney Transplantation
A Dose Escalation Study in de Novo Renal Transplantation
The purpose of this study is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of escalating doses of TCD601 when compared to rATG in de novo renal transplant patients.
- Trial name
- NCT04311632
- Testing
- TCD601, Tacrolimus (TAC), Corticosteroids (CS)
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- ITB-Med LLC
Stable Vitiligo
Efficiency of Fractional-Laser Resurfacing Followed by Topical Tacrolimus 0.03% Cream vs Tacrolimus Alone in Vitiligo
The aim the clinical trial was to find out whether fractional CO₂ laser sessions in combination with application of daily topical tacrolimus 0.03% would enhance the action of the drug and pose as a possible combination treatment…
- Trial name
- NCT03535051
- Testing
- fractional carbon dioxide laser, Tacrolimus Oint 0.03%
- Volunteers
- 27 people
- Sponsor
- Kasr El Aini Hospital
Kidney Transplantation
Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts
This is a multicentre study examining the use of Advagraf-minimization strategy and/or the use of an inhibitor of the renin-angiotensin system in reducing chronic rejection in renal allografts.
- Trial name
- NCT00933231
- Testing
- tacrolimus, Simulect, Cellcept
- Where
- 13 sites in Canada
- Volunteers
- 281 people
- Sponsor
- Astellas Pharma Inc
Liver Transplantation
Efficacy of Everolimus in Combination With Tacrolimus in Liver Transplant Recipients
This trial evaluated the efficacy and safety of Everolimus in combination with tacrolimus versus a standard immunosuppressive regimen concerning kidney function in liver transplant recipients.
- Trial name
- HEPHAISTOS (NCT01551212)
- Testing
- Everolimus, Tacrolimus, Corticosteroids
- Where
- 15 sites in Germany
- Volunteers
- 339 people
- Sponsor
- Novartis Pharmaceuticals
Ischemia Reperfusion Injury
Tacrolimus During the Implantation and the Effect on Ischemia-reperfusion Injury in Liver Transplantation
The evaluation of the efficacy of an intraportal infusion with Tacrolimus, at the time of liver graft implantation, compared to a control group without immunosuppressive intraportal infusion (Placebo: Saline solution 0.9%) with…
- Trial name
- TAC-Infusion (NCT00609388)
- Testing
- Tacrolimus, Saline solution 0.9% (250mL)
- Where
- Austria
- Volunteers
- 26 people
- Sponsor
- Medical University of Vienna
Transplantation
A Conversion Study to Assess Safety and Efficacy of a MR4 Based Immunosuppressive Regimen in Stable Kidney Recipients
Assessment of the safety and the efficacy of a tacrolimus modified release (MR4) based immunosuppressive regimen in stable kidney transplant subjects converted on a 1:1 (mg:mg) basis from a Prograf® based immunosuppressive…
- Trial name
- NCT00384137
- Testing
- Tacrolimus
- Where
- 13 sites in France, Germany and 4 more
- Volunteers
- 128 people
- Sponsor
- Astellas Pharma Inc
Cutaneous Lupus Erythematosus
Efficacy of Topical Tacrolimus in Different Subtypes With Cutaneous Lupus Erythematosus (CLE)
The purpose of this study is to evaluate the efficacy of topical tacrolimus in different subtypes of cutaneous lupus erythematosus.
- Trial name
- NCT00317681
- Testing
- Tacrolimus ointment
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Kidney Transplantation
Mycophenolate Mofetil (MMF) Discontinuation From a Tacrolimus/MMF/Steroid Triple Regimen After Kidney Transplantation
Patients after kidney transplantation received immunosuppression by Tacrolimus, MMF and steroids. In one half of the patients after 7 weeks MMF was reduced by half, and after 12 weeks it was stopped.
- Trial name
- DISTAMP (NCT00693381)
- Testing
- Tacrolimus, Mycophenolate Mofetil, methylprednisolone and prednisone
- Where
- 14 sites in Czechia, Hungary and 2 more
- Volunteers
- 152 people
- Sponsor
- Astellas Pharma Inc
Disorder Related to Renal Transplantation
Selection of Immunosuppression in Kidney Transplant Recipients Depending on Pre-transplant Donor-specific T-cell Reactivity.
The objective is to assess if low pre-transplantation donor specific T-cell reactive patients measured by Enzyme-linked immunosorbent spot (ELISPOT)assay can be safely managed with Calcineurin inhibitor(CNI)-free…
- Trial name
- SIRES (NCT01195194)
- Testing
- PRE-TRANSPLANT (PRE=before)
- Where
- 2 sites in Spain
- Volunteers
- 61 people
- Sponsor
- Josep M Grinyo
Kidney Transplantation
A Pharmacokinetic Analysis of Tacrolimus ER Dosing in Obese Kidney Transplant Recipients
Tacrolimus extended release (Astagraf) has recently been approved by the FDA as a once a day dosing regimen. This formulation has the potential to improve compliance.
- Trial name
- Tacrolimus ER (NCT02444143)
- Testing
- tacrolimus extended release
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Illinois Chicago
Neurotoxicity, Liver Transplant; Complications
Envarsus Neurotoxicity Burden in Liver Transplant Patients
This study will compare neurologic side effects associated with two immunosuppressant medications used in liver transplant patients.
- Trial name
- NCT03823768
- Testing
- Envarsus, Tacrolimus Immediate release
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Medical University of South Carolina
Transplant, Kidney
Pilot Trial for Implementation of a MPA PK Monitoring Strategy
This study is a prospective interventional trial of de novo renal transplant recipients, aiming to validate a strategy which combines the use of early post transplant MPA AUC sampling, and subsequent MPA trough level monitoring…
- Trial name
- MPA (NCT00187915)
- Testing
- Mycophenolate mofetil + Tacrolimus, Mycophenolate mofetil + Cyclosporin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Florida
Kidney Transplantation
A Study to Assess the Pharmacokinetics of a Modified-release Tacrolimus Based Immunosuppression Regimen in Stable Kidney Transplant Patients
A study to assess the pharmacokinetics, safety and effectiveness of tacrolimus in stable kidney transplant patients converted from a Prograf® based immunosuppression regimen to a modified release tacrolimus based…
- Trial name
- NCT00282568
- Testing
- Tacrolimus Modified Release (MR), tacrolimus
- Where
- 9 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- Astellas Pharma Inc
Graft Versus Host Disease
Hydroxychloroquine in Treating Patients With Newly Diagnosed Chronic Graft-Versus-Host Disease
RATIONALE: Hydroxychloroquine may decrease the immune response and be effective in treating chronic graft-versus-host disease. It is not yet known if standard therapy for graft-versus-host disease is more effective with or…
- Trial name
- NCT00031824
- Testing
- cyclosporine, hydroxychloroquine, prednisone
- Where
- 104 sites in United States, Australia and 4 more
- Volunteers
- 82 people
- Sponsor
- Children's Oncology Group
Hematopoietic Stem Cell Transplantation
A Study of Tacrolimus/Methotrexate and Tocilizumab to Prevent Acute Graft-Versus-Host Disease (AGVD) After Allogeneic Hematopoietic Stem Cell Transplant
This is a phase II open label trial designed to evaluate the efficacy of Tac/MTX/Toc in preventing graft versus host disease (GVHD).
- Trial name
- NCT02206035
- Testing
- Tacrolimus, Methotrexate, Tocilizumab
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- William R. Drobyski, MD
Arthritis, Rheumatoid
The Efficacy and Safety of Tacrolimus in Refractory Rheumatoid Arthritis Patients for 6 Months and Long-term Treatment
This study is designed to observed prospectively the efficacy and safety of 6 months and long-term treatment of Tacrolimus alone or with methotrexate (MTX) in moderate and severe Chinese RA patients who shown insufficiency…
- Trial name
- NCT02837978
- Testing
- Tacrolimus, MTX
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Qiang Shu
Leukemia, Lymphoma
Mycophenolate Mofetil, Tacrolimus, Daclizumab, and Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Monoclonal antibodies such as daclizumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00006350
- Testing
- daclizumab, therapeutic allogeneic lymphocytes, mycophenolate mofetil
- Where
- United States
- Sponsor
- University of Maryland, Baltimore
Pityriasis Alba
Clinical Trial of 0.0003% Calcitriol, 0.1% Tacrolimus, and Petrolatum for the Treatment of Pityriasis Alba
Pityriasis alba (PA) is a frequent cause of consultation in tropical areas due to its chronic course, trend to relapse and aesthetic impact. Currently, no treatment is widely accepted.
- Trial name
- NCT01388517
- Testing
- Tacrolimus, Calcitriol, Petrolatum
- Where
- Mexico
- Volunteers
- 39 people
- Sponsor
- Universidad Autonoma de San Luis Potosí
End Stage Renal Disease (ESRD)
Study of Myfortic in Combination With Tacrolimus and Thymoglobulin in Early Corticosteroid Withdrawal
To determine the safety and efficacy of a new formulation of Myfortic in combination with tacrolimus and thymoglobulin.
- Trial name
- NCT00374803
- Testing
- Mycophenolic Acid (Myfortic)
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- University of Cincinnati
Liver Transplant; Complications
ONSD and Neurotoxicity in Liver Transplant
This is a diagnostic test accuracy study. The investigators measure optic nerve sheath diameter (ONSD) by ultrasound on the eye during living donor liver transplantation operation at 5 minutes after reperfusion to predict the…
- Trial name
- NCT03799770
- Testing
- Optic nerve sheath diameter by ultrasound at 5 minutes post-reperfucion
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Mansoura University